ASND: Ascendis Pharma A/S
About
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Key Details
Market Cap
$7.44B
P/E Ratio
-15.37
1Y Stock Return
33.23%
1Y Revenue Growth
117.15%
Dividend Yield
0.00%
Price to Book
-68.5
Strategies that include ASND
Stock's related to ASND
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BRSP | 34.10% | $806.64M | -3.86% | 12.20% |
| CRSR | 32.63% | $689.97M | -47.32% | 0.00% |
| IEP | 32.43% | $5.70B | -31.12% | 31.39% |
| DLTR | 31.48% | $13.95B | -44.11% | 0.00% |
| TWO | 31.38% | $1.21B | -15.84% | 15.54% |
| SUM | 31.22% | $8.50B | +41.20% | 0.00% |
| FOLD | 31.22% | $2.84B | -11.52% | 0.00% |
| CMPR | 30.88% | $1.94B | +7.37% | 0.00% |
| NABL | 30.83% | $1.88B | -14.67% | 0.00% |
| CVCO | 30.74% | $3.82B | +69.11% | 0.00% |
| STHO | 30.57% | $150.51M | -5.99% | 0.00% |
| IVR | 30.49% | $495.56M | +2.38% | 19.70% |
| BLCO | 30.49% | $6.88B | +28.20% | 0.00% |
| AGNC | 30.33% | $8.56B | +9.64% | 14.95% |
| LOB | 30.28% | $2.08B | +41.52% | 0.26% |
| BPOP | 30.21% | $6.78B | +32.59% | 2.60% |
| MC | 30.05% | $5.22B | +66.66% | 3.25% |
| NEU | 29.87% | $5.13B | +3.54% | 1.82% |
| UCB | 29.82% | $3.91B | +35.08% | 2.86% |
| GBCI | 29.73% | $6.33B | +71.24% | 2.38% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| XGN | -0.02% | $62.26M | +127.74% | 0.00% |
| GIS | -0.04% | $34.85B | -2.91% | 3.78% |
| ACMR | -0.10% | $1.15B | +5.14% | 0.00% |
| COLL | 0.11% | $959.44M | +16.71% | 0.00% |
| AMN | 0.11% | $953.75M | -62.61% | 0.00% |
| QNTM | -0.12% | $9.19M | -94.36% | 0.00% |
| CQP | -0.12% | $25.90B | -6.77% | 5.96% |
| FLXS | 0.13% | $301.86M | +215.00% | 1.02% |
| MCK | -0.14% | $78.15B | +35.51% | 0.42% |
| LTM | 0.16% | $8.51B | -100.00% | <0.01% |
| QNRX | -0.19% | $3.20M | -85.07% | 0.00% |
| NOAH | -0.20% | $775.22M | -3.69% | 8.96% |
| WHLM | 0.29% | $17.64M | -29.34% | 0.00% |
| CMG | -0.31% | $80.02B | +33.62% | 0.00% |
| ACGL | 0.32% | $36.00B | +16.84% | 0.00% |
| CCEC | 0.34% | $1.02B | +28.03% | 3.26% |
| CVM | -0.36% | $41.17M | -73.98% | 0.00% |
| CPNG | -0.37% | $43.51B | +49.69% | 0.00% |
| ERIE | 0.37% | $19.39B | +46.23% | 1.23% |
| WRB | -0.40% | $22.94B | +29.98% | 0.69% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NEUE | -13.22% | $40.93M | -34.13% | 0.00% |
| HUSA | -11.33% | $16.69M | -11.56% | 0.00% |
| PGR | -10.49% | $149.10B | +57.29% | 0.45% |
| FYBR | -9.79% | $8.65B | +66.27% | 0.00% |
| LMT | -9.19% | $126.40B | +18.99% | 2.36% |
| CARV | -7.95% | $8.48M | -8.79% | 0.00% |
| ASPS | -7.91% | $22.36M | -80.26% | 0.00% |
| CME | -7.35% | $82.76B | +9.21% | 1.98% |
| BCAN | -7.13% | $72.87M | -99.75% | 0.00% |
| RILY | -7.00% | $145.72M | -79.86% | 20.75% |
| LITB | -6.96% | $35.48M | -75.45% | 0.00% |
| ERJ | -6.66% | $6.92B | +134.10% | 0.00% |
| EOG | -6.61% | $76.03B | +10.19% | 2.70% |
| BYRN | -6.61% | $479.70M | +295.19% | 0.00% |
| BEST | -6.44% | $31.65M | +3.88% | 0.00% |
| TTE | -6.24% | $138.45B | -11.95% | 5.50% |
| IRS | -6.11% | $1.22B | +117.95% | 4.11% |
| PRPO | -6.09% | $9.10M | -13.65% | 0.00% |
| LEU | -5.96% | $1.12B | +33.82% | 0.00% |
| EPM | -5.90% | $198.21M | +0.68% | 8.19% |
ETF's related to ASND
News
SeekingAlpha
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ETCompany ParticipantsJan Mikkelsen - President & Chief Executive...
Yahoo
– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1 2025 followed by MAA submission planned for Q3 2025 – SKYTROFA Q3 revenue of €47.2 million – 60%+ year-over-year volume growth offset by current and prior period sales deductions – Full year 2024 SKYTROFA revenue excluding sales deductions related to prior years expected to be €200 - €220 million, and fu
Finnhub
Ascendis Pharma Reports Third Quarter 2024 Financial Results - YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of...
Finnhub
Ascendis Pharma A/S Name, Registered Office and Objects of the Company: Article 1 ...
Yahoo
COPENHAGEN, Denmark, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2024 financial results and provide a business update on Thursday, November 14, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on November 14, 2024, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2024 financial results. Those who would like to participate may access the live webca
Yahoo
The market has been flat over the last week but is up 31% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability while aligning with these positive market trends.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.